Batman S, Bohn J, Weisenberger MW, et al. - Among patients suffering from Her2/neu-positive advanced or recurrent uterine papillary serous carcinoma (UPSC, which is a variant of endometrial cancer), this inquiry was undertaken to assess the cost effectiveness of carboplatin/paclitaxel alone vs carboplatin/paclitaxel with trastuzumab. To simulate management of a theoretical cohort comprising 4,000 patients observed for four years, experts designed a Markov model in TreeAge Pro 2019 software. Cost-effectiveness of the intervention was considered if the incremental cost-effectiveness ratio was below the willingness-to-pay threshold of $100,000 per QALY (quality-adjusted life year). Experts reported 637 fewer deaths and 627 fewer cases of progression in relation to treatment with the addition of trastuzumab vs treatment with carboplatin/paclitaxel alone. Therapy with trastuzumab was shown to be related to an additional expense of $144,335,895, but was linked with an increment of 2065 QALYs. Overall, addition of trastuzumab to carboplatin/paclitaxel was concluded as a cost-effective therapeutic strategy for patients suffering from advanced/recurrent Her2/neu-positive UPSC.